NCT05074758

Characterization of the microVAScular Dysfunction in Covid-19 ARDS

Characterization of the microVAScular Dysfunction in COvid-19 ARDS

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 40 (estimated)
• Sponsor: Assistance Publique - Hôpitaux de Paris · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary endpoint of this research is to establish that the alveolar dead space is significantly higher in patients with COVID-19 ARDS, compared to patients with non-COVID-19 ARDS. Secondarily, the investigators want to establish the prognostic value of the alveolar-dead space (measured iteratively) in patients with COVID-19 and non-COVID-19 ARDS, to establish the respective influences of the biological parameters of endothelial damage, of the biological parameters of coagulopathy, of the parameters set on the artificial ventilator on the value of the alveolar dead space; in ARDS patients with COVID-19 and non-COVID-19 ARDS, to establish the prognostic value of the laboratory parameters of endothelial damage and coagulopathy in patients with COVID-19 and non-COVID-19 ARDS.

Detailed description

Endothelial damage and coagulation activation at the lung microvascular level may play an important role in the physiopathology of the COVID-19 ARDS. The project aims to prospectively investigate both bedside pulmonary physiological markers and biological markers of coagulopathy and endothelial dysfunction in COVID-19 and non-COVID-19 ARDS patients.

Conditions

• ARDS, Human
• COVID-19 Acute Respiratory Distress Syndrome

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	alveolar dead-space quantification	measurement of alveolar dead-space based on volumetric capnography
DIAGNOSTIC_TEST	Coagulation activation and impaired fibrinolysis explorations	blood sampling: * Fibrinolytic components * NETs components * Elastase-derived fragments of proteins of interest
DIAGNOSTIC_TEST	Endothelial activation / endothelial senescence	circulating endothelial cells, E-selectin, endoglin, LVEF-A, LVEFR-2, Angiopoietin -1 and -2, cKit and SDF-1 Willebrand factor (activity, antigen, multimeric analysis )

Timeline

• Start date: 2021-12-10
• Primary completion: 2022-09-10
• Completion: 2022-09-10
• First posted: 2021-10-12
• Last updated: 2022-01-19

Locations

1 site across 1 country: France